[Review] Consensus position statement on advancing the classification of patients and tests of cure in studies of antibiotic treatment of complicated urinary tract infections

Di |2025-05-14T00:30:01+02:00Maggio 14th, 2025|Categorie: Coronavirus Lancet|

Complicated urinary tract infections denote an important research field for new antibiotics against Gram-negative pathogens. There is, however, increasing concern that this disease entity is too vaguely defined, leading to heterogeneous study populatio...

[Correspondence] Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials

Di |2025-05-10T00:30:02+02:00Maggio 10th, 2025|Categorie: Coronavirus Lancet|

In their recent Review, Ramos and colleagues1 summarise the evolving landscape of pneumococcal disease and vaccines. However, two crucial issues warrant further discussion. First, many countries recommend adult pneumococcal vaccination using a risk-bas...

[Comment] Continuous on-site mentoring for infection prevention and control and antimicrobial stewardship programmes in war-affected settings: the example of Ukraine

Di |2025-05-07T00:30:01+02:00Maggio 7th, 2025|Categorie: Coronavirus Lancet|

Antimicrobial resistance (AMR) remains one of the most critical public health threats globally, and Ukraine is no exception. Even before the Russian full-scale invasion in 2022, Ukraine faced substantial challenges in controlling AMR.1 The ongoing war ...

[Articles] Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case–control study

Di |2025-05-06T00:30:01+02:00Maggio 6th, 2025|Categorie: Coronavirus Lancet|

These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation from birth to age 3 months and sustained to age 6 months.

[Corrections] Correction to Lancet Infection 2025; published online April 16. https://doi.org/10.1016/S1473-3099(25)00088-X

Di |2025-05-01T00:30:03+02:00Maggio 1st, 2025|Categorie: Coronavirus Lancet|

Dahmann S, Kueckelhaus M, Wiebringhaus P, et al. Maternal mastitis and streptococcal toxic shock syndrome risk from breastfeeding children with scarlet fever: case report and literature review. Lancet Infect Dis 2025; published online April 16. https:/...

[Articles] Estimated undertreatment of carbapenem-resistant Gram-negative bacterial infections in eight low-income and middle-income countries: a modelling study

Di |2025-05-01T00:30:01+02:00Maggio 1st, 2025|Categorie: Coronavirus Lancet|

Infections caused by CRGN bacteria are likely to be significantly undertreated in LMICs. To close this treatment gap, improved access to diagnostics and antibiotics, strengthening of health systems, and research to identify gaps in the treatment pathwa...

[Articles] Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial

Di |2025-04-26T00:30:03+02:00Aprile 26th, 2025|Categorie: Coronavirus Lancet|

These findings confirm previously observed safety and immunogenicity profiles of VLA15 in adults and extend them to children aged 5 years and older and adolescents. The greater immunogenicity of VLA15 among children and adolescents might translate to i...

Torna in cima